Who are Anti-hypertensive drug treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, A3, Valsartan/aliskiren, Losartan Tablets, Placebo to Telmisartan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-hypertensive-drug-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-hypertensive drug treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-hypertensive drug treatment (Anti-hypertensive drug treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker. Area: Cardiovascular.

phase 2 Angiotensin II receptor blocker AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Anti-hypertensive drug treatment (Anti-hypertensive drug treatment) — Universidade Gama Filho. Blocks the action of angiotensin II at its receptor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-hypertensive drug treatment TARGET	Anti-hypertensive drug treatment	Universidade Gama Filho	phase 2	Angiotensin II receptor blocker	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
A3	A3	Breath of Life International Pharma Ltd	marketed	Angiotensin receptor blocker	AT1 receptor
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)
Losartan Tablets	Losartan Tablets	Istituto Auxologico Italiano	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Placebo to Telmisartan	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin II receptor blocker class)

Universidade Gama Filho · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-hypertensive drug treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-hypertensive-drug-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab